05th December, 2019

To,
BSE Limited,
25, P. J. Towers,
Dalal Street,
Mumbai – 400 001
Ref: Company Scrip Code: 532834

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051
Ref: Symbol: CAMLINFINE | Series: EQ

Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - (“SEBI LODR”)

This is to inform you that the senior management team of the Company shall engage in a conference with the HDFC Securities’ Investor Forum, to be held on 06th December, 2019 in Mumbai.

Further to our intimation about the meet with Analysts/Investors as scheduled, please find enclosed herewith the investor presentation made on the aforesaid meet.

It is clarified that the presentation and the information contained therein does not constitute or form part of an invitation or solicitation to offer to purchase or subscribe to any securities of the Company in any jurisdiction. This presentation has been prepared for information purposes only. The information contained in the investor presentation is not to be taken as any recommendation made by the Company or any other person to enter into any agreement with regard to any investment.

We request you to take the above on record and the same be treated as compliance under the applicable Regulations of SEBI LODR.

Note: The date of the scheduled call is subject to change due to exigencies on the part of Investors/Company.

Thanking You,
Encl.: a/a.
For Camlin Fine Sciences Limited

(Lavanya Rastogi)
Ass. Company Secretary & Compliance Officer

Registered Office:
Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400093, India.
CIN: L74100MH1993PLC075363
+91 22 6700 1000 +91 22 2832 8400
slinfo.in@camlinfs.com www.camlinfs.com
Executive Summary

Company Overview

- Camlin Fine Sciences Limited (CFS), formed in 2006 after demerging the fine chemical business from Camlin Ltd., is a vertically integrated company engaged in research, development, manufacturing, commercializing and marketing of specialty chemicals and blends, which are used in a wide array of sectors.
- CFS is global leading producer of food antioxidants, such as TBHQ & BHA, and the world’s 3rd largest producer of Vanillin.

FY19 Business Mix (Revenue Share %)

- Shelf Life Solutions (54%): Includes Anti-oxidants, Blends and Additives
- Performance Chemicals (27%): Includes Specialty Chemicals
- Aroma Chemicals (17%): Includes Vanillin and Ethyl Vanillin

Manufacturing Facilities, R&D Centres and Application Labs

- Manufacturing Facilities in India, Brazil, China, Mexico and Italy
- R&D Centres at Tarapur (India) and Ravenna (Italy)
- Application Labs in India, Brazil, North America, Italy and Mexico

Financials FY19 Consolidated (INR Mn)

- Operational Revenue: 8,922
- EBITDA: 693*
- Net Worth: 4,303#

* Excluding Other Income & Foreign Exchange Fluctuation Gain/(Loss)
# Including non controlling interest
<table>
<thead>
<tr>
<th><strong>Snapshot</strong></th>
<th><strong>One of the few Vertically and Backward Integrated player</strong></th>
<th><strong>Leading Manufacturers of Antioxidants in the world with more than 25 years of experience</strong></th>
<th><strong>3rd Largest producer of Vanillin in the world</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Serving more than 80 countries with over 100 products</strong></td>
<td><strong>Preferred Partner for manufacturing customized products</strong></td>
<td><strong>Strategic move to start blends which have higher margins</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>5 Manufacturing Facilities, 2 R&amp;D Centres and 5 Application Labs</strong></td>
<td><strong>Global expertise, local solutions</strong></td>
<td><strong>Strong management team with experienced industry professionals</strong></td>
</tr>
</tbody>
</table>
COMPANY OVERVIEW
About the Company

- In 2006, Camlin Fine Sciences Limited (CFS) was formed after de-merging (mirror shareholding) the fine chemical business from Camlin Ltd.
- The Company has over 30 years of experience providing innovative solutions with a competitive advantage in fine sciences.
- CFS is a vertically integrated company, engaged in research, development, manufacturing, commercializing and marketing of specialty chemicals and blends, which are used in a wide array of sectors.
  - Food, feed, animal and pet nutrition
  - Flavours & Fragrance
  - Pharma
  - Agro Chemicals
  - Performance Chemicals
  - Blends
  - Shelf-life Extension
  - Aroma Chemicals
  - Others
- CFS categorizes their business into 3 different verticals based on their product portfolio, namely: Shelf-Life Solutions (which include anti-oxidants, its blends and additives), Performance chemicals and Aroma Chemicals.
- CFS has subsidiaries in Mexico, North America, China, Europe and Brazil serving in more than 80 countries with more than 100 products and over 1,000 satisfied customers.
- CFS markets its products in Europe, Asia Pacific (including India), North Africa, Middle East, South, Central and North America.

Total Operational Revenue (INR Mn)

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY16</td>
<td>5,042</td>
</tr>
<tr>
<td>FY17</td>
<td>5,469</td>
</tr>
<tr>
<td>FY18</td>
<td>7,228</td>
</tr>
<tr>
<td>FY19</td>
<td>8,922</td>
</tr>
<tr>
<td>H1-FY20</td>
<td>4,824</td>
</tr>
</tbody>
</table>

H1-FY20 Operational Revenue Breakup

- Performance Chemicals 25%
- Blends 31%
- Shelf-life Extension 23%
- Aroma 17%
- Others, 4%
Board of Directors

Mr. Dilip Dandekar - Chairman
• Been with the Company since 2006 and has long and vast experience in Marketing, Administration and overall Management.

Mr. Ashish Dandekar – Managing Director
• BA in Economics and Management studies form Temple University, USA.

Mr. Pramod M. Sapre – Independent Director
• BSc and Diploma in Marketing Management with varied experience in Marketing of Pharmaceutical Products.

Mr. Sharad M. Kulkarni - Independent Director
• Degree of Engineering from University of Pune.
• Acts as a Business Advisor and Management Consultant to several Indian and International companies and his areas of expertise covers Business Development, International Alliance Management, Strategic Planning.

Mr. Bhargav A. Patel - Independent Director
• Has industrial expertise with an MBA from an US University.
• Wide experience in the field of Engineering, Textile Machinery and Leather industry.

Mr. Abeezar E. Faizullahbho - Independent Director
• Bachelor of Law from University of Mumbai and Solicitor from Bombay Incorporated Law Society.
• Has expertise in Litigation, Alternate Dispute Resolution and Corporate Commercial Law.

Ms. Anagha Dandekar – Non-Executive Director
• MBA in Finance from University of South Carolina, USA.
• President, co-founder of Hardware Renaissance, a manufacturer of high-end, hand crafted door hardware and accessories.

Mr. Atul R. Pradhan - Independent Director
• Holds Diploma in Electronics and Electrical Communication Engineering and MBA.
• Senior business advisor with more than 25 years of experience in Management Consultancy industry.

Mr. Nicola Paglietti - Independent Director
• Masters in Law and member of the Bar of New York and Rome and possesses over 20 years of professional experience in Contracts and Corporate law.

Mr. Nirmal V. Momaya - Non-Executive Director
• CA with over 25 years of experience in Finance, Taxation, Audit and Management consultancy.
• Founder at Pagoda Advisors Pvt. Ltd. with a focus on consulting for various businesses as well as advising CFS on important business and strategic matters since 2009.

Mr. Arjun Dukane – Executive Director - Technical
• Chemical Engineer with 31 years of experience in the Chemical Industry and has been associated with CFS for about 12 years.

Mr. Ajit S. Deshmukh - Non-Executive Director
• BE in Electronics and Post Graduate from NCST.
• Over 20 years experience in management and leadership of IT and Investment Banking industry.
### Key Milestones

<table>
<thead>
<tr>
<th>Year</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1993 | • Camlin Fine Chemical division incorporated in Camlin Ltd. to manufacture antioxidants for the global market.  
  • Ultra-modern manufacturing plant was set up in Tarapur, Maharashtra. |
| 2006 | • Camlin Fine Sciences Ltd. was formed after demerging (mirror shareholding) the fine chemical business from Camlin Ltd. |
| 2011 | • Acquired Borregaard Italia SpA, a manufacturing facility in Italy producing Hydroquinone and Catechol.  
  • Integrated manufacturer of Diphenols. |
| 2013 | • Introduced extensive range of performance chemicals like MEHQ, Vetratrole, Guaiacol, etc. |
| 2014 | • Launched Aroma and Flavoring Compounds - Vanillin |
| 2015 | • Commencement of production and marketing of antioxidant blends in Brazil through 100% subsidiary ‘CFS do Brasil Ltd’.  
  • Setting up of application laboratories, fully supported by a group of technical team. |
| 2016 | • Acquired 65% stake in Dresen Quimica S.A.P.I.de C.V., Mexico along with its 5 subsidiaries in Mexico, Peru, Guatemala, Columbia and Dominican Republic to expand its market reach in Central & South America along with few parts of Latin America.  
  • Launch of CFS North America, LLC. |
| 2017 | • Acquired 51% stake through SPA in Ningbo Wanglong Flavours and Fragrances Company Ltd. and became the 3rd largest producers of Vanillin in the world.  
  • Entered into a preferred supply agreement with Lockheed Martin Advanced Energy Storage for manufacture and supply of a specialty chemical. |
  • Commenced construction of the Dahej Plant for Diphenols. |
Major Clients
Key Strengths

- Vertically integrated across the value chain
- Diversified customer base
- Preferred Partner for manufacturing customized products
- Proven ability to acquire and improve business performance
- Local presence in global markets
- Advanced R&D facilities & Application Labs
- Experienced promoters and professional management team
- Global player in shelf-life solutions across food, feed, pet-food and biodiesel
- Diversified customer base
- Vertically integrated across the value chain
MANUFACTURING OVERVIEW
Geographical Presence

- **Ravenna, Italy**
- **Mexico City**
- **Guatemala**
- **Peru**
- **Iowa, USA**
- **Yuyao, Zhejiang, China**
- **Indaiatuba, Brazil**
- **Colombia**
- **Cuba**
- **Argentina**
- **Chile**
- **Denmark**
- **Mahad, Mumbai**
- **Khopoli**
- **Tarapur**

- **Owned Plants**
- **Outsourced Manufacturing**
- **Blending Facility**
- **R&D/ Food Labs**
- **Marketing offices**
## Manufacturing Plants

<table>
<thead>
<tr>
<th>Countries</th>
<th>CFS India</th>
<th>CFS Mexico</th>
<th>CFS Europe</th>
<th>CFS Brazil</th>
<th>CFS Wanglong</th>
<th>CFS North America</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Business heads</strong></td>
<td>Ashish Dandekar (Managing Director)</td>
<td>Arturo Paulin (Manager)</td>
<td>Dr. Massimo Cupello Castagna (Managing Director)</td>
<td>Luciano Monteiro (General Manager)</td>
<td>Gautum Sapute (Head of operations)</td>
<td>Jennifer Igou (General Manager)</td>
</tr>
<tr>
<td><strong>Products</strong></td>
<td>Shelf Life Solutions, Aroma &amp; Performance Chemicals</td>
<td>Shelf Life Solutions</td>
<td>Performance Chemicals &amp; Shelf Life Solutions</td>
<td>Shelf Life Solutions</td>
<td>Vanillin (Aroma)</td>
<td>Shelf Life Solutions</td>
</tr>
<tr>
<td><strong>Capacity (in MT)</strong></td>
<td>15,000</td>
<td>12,000</td>
<td>12,000</td>
<td>6,000</td>
<td>4,200</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Employee Strength</strong></td>
<td>350+</td>
<td>130+</td>
<td>50+</td>
<td>30+</td>
<td>75+</td>
<td>10+</td>
</tr>
<tr>
<td><strong>Customers</strong></td>
<td>500+</td>
<td>400+</td>
<td>15+</td>
<td>85+</td>
<td>15+</td>
<td>15+</td>
</tr>
<tr>
<td><strong>Photos</strong></td>
<td><img src="image1" alt="Image" /></td>
<td><img src="image2" alt="Image" /></td>
<td><img src="image3" alt="Image" /></td>
<td><img src="image4" alt="Image" /></td>
<td><img src="image5" alt="Image" /></td>
<td><img src="image6" alt="Image" /></td>
</tr>
</tbody>
</table>
Integrated Value Chain

Key Raw Material

Diphenols

- Hydroquinone
- Catechol

Commodity chemical

- Phenol

- Ascorbyl Palmitate¹
- Blends
- Shelf Life Solutions
- Performance Chemicals
- Aroma

- TBHQ
- MEHQ
- Other derivatives of HQ
- Guaiacol
- Veratrole
- Other derivatives of Catechol
- Guethol
- Vanillin
- Ethyl Vanillin

Fully integrated from Diphenols to step down derivatives, antioxidant blends and Vanillin, therefore reducing the risk of supply chain disruptions.

¹ Ascorbyl Palmitate is not a part of HQ / Catechol value-chain and is manufactured from ascorbic acid.
Global Research & Development

Application Labs
• Develops customized blends for various applications
• Provides technical assistance and development support to customers
• Tests of defined performance parameters
• Conducts stability studies for various products of shelf life

R&D Labs
• Develops new products and does value additions to existing products
• Develops customised products
• Improves products and processes
• Catalyst application & development
• Focuses on developing derivatives of HQ and Catechol

Pilot Plant
• It has the ability to run small batch sizes and stabilize the processes before commercial scale manufacturing
• Improves processes

Central America, Andean States and Caribbean Islands
North America
Asia and the rest of the World
Latin America
Certifications

ISO 2015

FSAAI Certificate

FSSC 22000

Halal Certificate

Kosher TBHQ & BHA

Kosher Vanillin, Ethyl Vanillin, TBC, BHT, ASP etc. (10 products)

Kosher Intense Green & Vetigreen

FAMI QS
BUSINESS OVERVIEW
Business Mix

Shelf-Life Solutions* (54%)
- Food
- Pet food
- Animal Nutrition
- Rendering
- Aqua Culture
- Bio-fuels

Performance Chemicals* (25%)
- Pharma Intermediates
- Agrochemicals
- Dyes and Pigments
- Petrochemicals

Aroma Chemicals* (17%)
- Feed & food
- Consumer
- Incense Sticks
- Flavours & Fragrances
- Pharmaceuticals

*As on H1-FY20
Shelf Life Solutions Industry Overview

- Shelf life Solutions are solutions in terms of both - increasing shelf life and food safety options which help preserve color, freshness, safety of the product.
- The **addressable market** caters to human food, pet food, animal nutrition, aquaculture and biodiesel industry and is about **USD 6-7 Bn**.
- These solutions are **Feed Safety solutions, Health and Performance solutions** which are made from synthetic antioxidants like TBHQ, BHA or natural antioxidants like rosemary extract and green tea.
- The **Global Cooking Oil Market** was valued at around USD 86 Bn in 2017 and is expected to reach approximately USD 130 Bn by 2024, growing at a CAGR of around 6.2% between 2018 and 2024.
- The **Global Pet Food Market** was estimated at a value of about USD 79 Bn in 2017. The industry is forecasted to register a CAGR of 5.03%, during 2017-2024. Rising need for nutritious, healthy, and organic pet food on account of increasing awareness regarding animal health is expected to augment market demand.
- The **Global Biodiesel Market** is expected to reach USD 55 Bn by 2025. The market is expected to witness growth at 7.3% CAGR owing to increasing demand for biodiesel as automobile fuel owing to their environment friendly characteristic to mitigate greenhouse gas emission is expected to propel industry growth.
- The **Animal Feed Processing Market** is estimated at USD 22 Bn in 2018 and is projected to reach USD 27 Bn by 2023.

(Source : Mordor Intelligence, Globe Newswire, Grandview Research, allaboutfeed.net, Company)
CFS - Shelf-Life Solutions

• CFS is one of the leading global antioxidants manufacturer and a trusted name in the antioxidant industry for more than 25 years.
• The Company provides solutions for shelf life needs of human food, pet food, rendering and animal nutrition industries and biodiesel.
• Products primarily include antioxidants which are either synthetic or natural and sold in liquid and dry solutions.
• The products are used to delay certain types of cell damage, by stopping the chain reaction of oxidation, thereby keeping the food fresh. Simply, they are additives to preserve processed foods.
• CFS has brands like Xtendra Bake Magic, Mithai Magic, Baker’s Bread, Nasure etc.
• The NaSure range of plant-based antioxidant solutions offer the consumers a natural alternative in shelf life extension.
• Vertically integrated platform gives the reliability one needs from a supplier, backed by an experienced team and a global supply chain network which is present across North America, Central America, South America, Asia Pacific (including India), and Europe.

Total Operational Revenue (INR Mn)

<table>
<thead>
<tr>
<th></th>
<th>FY16</th>
<th>FY17</th>
<th>FY18</th>
<th>FY19</th>
<th>H1-FY20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shelf Life Extension (Ingredients)</td>
<td>3,612</td>
<td>1,667</td>
<td>2,035</td>
<td>2,231</td>
<td>1,110</td>
</tr>
<tr>
<td>Blends</td>
<td>22</td>
<td>1,327</td>
<td>1,571</td>
<td>2,587</td>
<td>1,495</td>
</tr>
</tbody>
</table>

Brands

CFS - Shelf - Life Solutions

<table>
<thead>
<tr>
<th></th>
<th>FY16</th>
<th>FY17</th>
<th>FY18</th>
<th>FY19</th>
<th>H1-FY20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shelf Life Extension (Ingredients)</td>
<td>3,612</td>
<td>1,667</td>
<td>2,035</td>
<td>2,231</td>
<td>1,110</td>
</tr>
<tr>
<td>Blends</td>
<td>22</td>
<td>1,327</td>
<td>1,571</td>
<td>2,587</td>
<td>1,495</td>
</tr>
</tbody>
</table>

CFS - Shelf - Life Solutions

<table>
<thead>
<tr>
<th></th>
<th>FY16</th>
<th>FY17</th>
<th>FY18</th>
<th>FY19</th>
<th>H1-FY20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shelf Life Extension (Ingredients)</td>
<td>3,612</td>
<td>1,667</td>
<td>2,035</td>
<td>2,231</td>
<td>1,110</td>
</tr>
<tr>
<td>Blends</td>
<td>22</td>
<td>1,327</td>
<td>1,571</td>
<td>2,587</td>
<td>1,495</td>
</tr>
</tbody>
</table>
Global Antioxidants Market

- Antioxidants are amongst the valuable ingredients used in the food beverage, fuel additives, animal feed, cosmetics and synthetic resins industry.
- Synthetic antioxidants are largely used in Edible Oil followed by Packaged Foods, Confectionary, Bakery, Beverages and Meat, Pet food, Biodiesel, Animal feed, Rubber, Cosmetics and Petroleum products.
- The Synthetic Antioxidants Market is expected to grow at a CAGR of 5.32% during 2016-2022.
- Natural antioxidants are substances or nutrients found in food. Naturally occurring antioxidants include rosemary extract, tocopherols and green tea. Fruits and vegetables are the top sources of natural antioxidants.
- The Natural Antioxidant Segment is expected to grow at a CAGR of 7.47% during 2016-2022.

Antioxidant Applications

- Synthetic Resin, 53%
- Food Products, 14%
- Cosmetics, 12%
- Fuel Additives, 11%
- Animal Feed, 6%
- Others, 4%

(Source : prnewswire, Allied Market Research, Technavio insights report, Company)
## TBHQ

**Characteristics:**
- Increasing shelf life of edible oils.
- Protection of fats produced from these oils like margarine.
- Increasing frying cycles of the edible oil, i.e., how many times you can use the oil to cook food.

**Applications:**
- Packaged Oil, Margarine, Frying Oil, Specialty Fats etc.
- Pasta, instant noodles and fried food like samosa, chips, etc.
- Baked goods like breads, cookies and cakes
- Indian mithais like peda and halwa
- Biofuels

## BHA

**Characteristics:**
- Stability to lard and tallow, i.e. fat extracted from pigs and beef after rendering.
- Stability to vitamin Pre mix which is added to pet food.
- Shelf life to pet food (derived from healthiest animal fat).
- Shelf life to animal feed (derived from lower quality animal fat).

**Applications:**
- Rendering
- Animal feed and performance enhancers
- Finished pet food
- Prawn and shrimp farming
- Fresh Meat / Slurry

## Natural Antioxidants

- Green tea extracts
- Rosemary extracts
- Tocopherols
- Acerola extract

## Synthetic Antioxidants

## Antimicrobials

- Agents used in killing the growth of bacteria and fungi
- Primarily used in bakery items, Indian mithais and forage (plant livestock feed on)
CFS - Blends

• CFS transitioned from selling the anti-oxidants as a commodity to making blends which command higher margins in 2016.
• Today the company has over **100+ formulation blends** which are a combination of various anti-oxidants like TBHQ, BHA, BHT, Ascorbyl Palmilate and Propyl Gallate.

Blenders:
They make ‘blends’ from anti oxidants

Gross Margins:
35-40%

Customer:
‘Blends’ are sold to end consumers (food companies)

Gross Margins:
30-35%

Camlin:
Produces anti oxidants like TBHQ and BHA

Gross Margins:
35-40%

Blends cater to markets like:
• Human food - edible oils and specialty fats from these oils and fried snacks etc.
• Animal feed – products like acidifiers, enzymes, energizers, toxin and pellet binders in feed for poultry, horse, swine, broiler, cattle, aqua etc.
• Bio-diesel
• Rendering
• Pet food – additives to make the food more palatable, retain the vitamin premix, fats and protein and increase shelf life

This segment contributes around double the revenue compared to plain TBHQ, BHA business and has immense future growth opportunities.

• CFS has 5 Application labs which cater to their own geographical presence. They study the local market and approach customers with tailor made solutions.
• CFS is now directly selling it to customers instead of selling to blenders, hereby increasing the customer base from 40 to 1,000 customers since 2014.
CFS - Performance Chemicals

- CFS’s Performance Chemicals are HQ, Catechol and their downstreams.
- Most specialty chemicals are organic chemicals that are used in a wide range of every day products used by consumers and industry.
- They are used as polymerisation stabilisers for specialty polymers used in automotive industry, electronic industry and petrochemical industry.
- Application in manufacturing of agrochemicals, pharmaceuticals intermediaries, dyes and pigments.
- CFS has entered into a long-term preferred supply agreement with Lockheed Martin Advanced Energy Storage, USA for a speciality chemical.

Industries covered:
- Petrochemicals
- Pharmaceuticals
- Agrochemicals
- Dyes & Pigments
- Polymers
- Adhesives

Total Operational Revenue (INR Mn)

<table>
<thead>
<tr>
<th>Year</th>
<th>FY16</th>
<th>FY17</th>
<th>FY18</th>
<th>FY19</th>
<th>H1-FY20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>1,153</td>
<td>2,148</td>
<td>2,457</td>
<td>2,409</td>
<td>1,206</td>
</tr>
</tbody>
</table>
Performance Chemicals are specialty chemicals sold on the basis of their performance for specific applications. Hence named ‘Performance Chemicals’. They are unique or formulated based on requirements of customers to provide innovative solutions.

**Performance Chemicals**

**MEHQ**
- Stabiliser for Acrylic Acid, Methacrylic Acid
  - **Applications**
    - Plastics, Adhesives, Rubbers, Elastomers, Super Absorbent Pulp
  - **Industry**
    - Construction, Automobile sports, fitness, Cosmetic, Health, Water Treatment, Paints and Coatings

**TBC**
- Stabiliser for Butadiene and Styrene
  - **Applications**
    - Acrylonitrile, Butadiene Styrene, Styrene Butadiene Rubber, Poly Butadiene Rubber
  - **Industry**
    - Automobile and Textile Industry

**Guaiacol**
- • Vanillin – (Flavour and Fragrance)
- • Guaphenesin – (cough and cold)
- • Carvedilol – (cardio)
- • Methacarbomol – (muscle relaxant)
- • Iobornyl Cyclohexane – (Fragrance)

**Veratrole**
- • Agrochemicals – Fungicide and Herbicides
- • Pharmaceuticals -
  - • Verapamil - cardio
  - • Mebeyverine - anti spasm
  - • Prazosin - cardio
  - • Donepezil - anti alzhiemers

**Other Derivatives**
- • **Guethol** - Ethyl Vanillin (Flavour and Fragrance)
- • **CME** - Dyes and pigments
- • **Ortho Diethoxy Benzene**
- • **Drotavarin** (drug)
- • **Dicoquinate** (vet drug)
- • **Parabenzoquinone** - Agrochemical intermediates
Vanillin Market

- Vanillin is used in food & beverages, to enhance sweetness in food products, such as chocolates, biscuits, candy, ice-creams, and cakes.
- The growing demand for these food products across the globe, is expected to boost the demand for vanillin. Further, the developing interest for vanillin in the bakery & confectionery industry and the extensive use as a flavouring agent are some of the factors projected to fuel the growth of global vanillin market.
- The global Vanillin market is expected to reach USD 725 Mn by 2025 with an expected CAGR of 8.4%.
- The Synthetic Vanillin market covers over 97% of the overall demand compared to Natural Vanillin.
- The Natural Vanillin, derived from orchid pods, represented less than 1% of the overall industry size and was over 60 tons, in 2015.
- Major Players – Solvay, Jiaxing Zhonghua, CFS, Borregard and Thrive.

Global Vanillin Market in Revenues (USD Mn)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Value</td>
<td>642</td>
<td>676</td>
<td>714</td>
<td>756</td>
<td>800</td>
<td>843</td>
<td>885</td>
</tr>
</tbody>
</table>

Region wise Vanillin Consumption (CY16)

- North America, 32%
- Europe, 24%
- Asia Pacific, 19%
- South & Central America, 13%
- Africa, 12%

Source: Grandview research, Mordor Intelligence
CFS - Aroma Chemicals

• CFS produces Vanillin through Catechol route and is most trusted by the Food and Flavours Industry.
• Vanillin is a synthetic substitute to vanilla as it is very expensive and labour intensive to produce.
• The Company is the 3\textsuperscript{rd} largest Vanillin manufacturer in the world with 100\% backward integration.
• 95 \% of products use Vanillin in their ingredients, except the high end products.
• The company also manufactures other Aroma chemicals.

Brands under Vanillin

VANESSE \textsuperscript{\textregistered}

The world’s preferred choice of pure Vanillin.

Evani\textsuperscript{\textregistered}

Ethyl Vanillin, is 3 times more potent than Vanillin and offers a more concentrated flavour profile.

Other products under Aroma

<table>
<thead>
<tr>
<th>Total Operational Revenue (INR Mn)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY16</td>
</tr>
<tr>
<td>163</td>
</tr>
</tbody>
</table>

Total Operational Revenue (INR Mn)
Growth Strategy

To shift the focus from anti-oxidant ingredients to anti-oxidant blends and additives

To create a sustainable business by diversifying into different geographies and different derivative applications

To commercialize Dahej SEZ facility making CFS the 2nd largest producer of HQ and Catechol in the world

To innovate and develop natural and organic chemical products

To capitalize on the strong R&D team and knowledge and innovate value added and sustainable chemicals

To continue to grow in the Vanillin & flavours and fragrance industry
Update on Dahej Project

Work / Activities completed

- Financial Closing achieved
- Basic Process & Mechanical Equipment Engineering
- Long lead equipment (process & utility) as well as major equipments – Orders received except Boiler
- Civil / Structural Engineering for major non-process buildings, compound hall, Warehouse
- Civil Contractors / Engineering Head / Third Party Inspection Agency / Construction Management Company appointed
- Office staff / Production head / Instrumentation head / Security Agency appointed
- Water & Electricity connections in place & HAZOP study done
- Detailed process Engineering - Electricals
- Engineering of Piping, Instrumentation & Controls
- Civil work of internal roads & area grading
- Construction of Plant Building, Cooling Towers, storage tanks, admin building, pipe racks in progress
- Piping work in progress
- Pre-construction activity of Solvent Area, Tank Farms, Substations, etc.

Work in progress

- 95% of the project is completed
- Water trials have been commenced
- Mechanical completion is expected in last week of November 2019
- Trial runs expected after mechanical completion
- Delay of 3-4 weeks expected due to persistent monsoon

Time line

Commercial production most likely expected in January 2020
FINANCIAL OVERVIEW
## Standalone Income Statement

<table>
<thead>
<tr>
<th>Particulars (INR Mn)</th>
<th>FY17</th>
<th>FY18</th>
<th>FY19</th>
<th>H1-FY20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operational Income</td>
<td>3,376</td>
<td>4,050</td>
<td>5,481</td>
<td>2,871</td>
</tr>
<tr>
<td>Total Expenses</td>
<td>3,156</td>
<td>3,996</td>
<td>5,182</td>
<td>2,585</td>
</tr>
<tr>
<td>EBITDA</td>
<td>220</td>
<td>54</td>
<td>299</td>
<td>286</td>
</tr>
<tr>
<td><strong>EBITDA Margin</strong></td>
<td>6.52%</td>
<td>1.33%</td>
<td>5.46%</td>
<td>9.96%</td>
</tr>
<tr>
<td>Depreciation</td>
<td>116</td>
<td>91</td>
<td>91</td>
<td>56</td>
</tr>
<tr>
<td>Finance Cost</td>
<td>232</td>
<td>236</td>
<td>203</td>
<td>144</td>
</tr>
<tr>
<td>Other Income</td>
<td>129</td>
<td>92</td>
<td>137</td>
<td>56</td>
</tr>
<tr>
<td>Exceptional Items</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PBT</td>
<td>1</td>
<td>(181)</td>
<td>142</td>
<td>142</td>
</tr>
<tr>
<td>Tax</td>
<td>9</td>
<td>(39)</td>
<td>35</td>
<td>47</td>
</tr>
<tr>
<td>Profit After Tax</td>
<td>(8)</td>
<td>(142)</td>
<td>107</td>
<td>95</td>
</tr>
<tr>
<td><strong>PAT Margin</strong></td>
<td>NA</td>
<td>NA</td>
<td>1.95%</td>
<td>3.31%</td>
</tr>
<tr>
<td>Other Comprehensive Income</td>
<td>(1)</td>
<td>1</td>
<td>(3)</td>
<td>(4)</td>
</tr>
<tr>
<td><strong>Total Comprehensive Income</strong></td>
<td>(9)</td>
<td>(141)</td>
<td>104</td>
<td>91</td>
</tr>
<tr>
<td>Diluted EPS (INR per share)</td>
<td>(0.23)</td>
<td>(1.63)</td>
<td>0.88</td>
<td>0.78</td>
</tr>
</tbody>
</table>
### Standalone Balance Sheet (IND-As)

<table>
<thead>
<tr>
<th>Particulars (INR Mn)</th>
<th>FY18</th>
<th>FY19</th>
<th>H1-FY20</th>
<th>Particulars (INR Mn)</th>
<th>FY18</th>
<th>FY19</th>
<th>H1-FY20</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EQUITY</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>Non-Current Assets</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a) Equity Share Capital</td>
<td>121</td>
<td>121</td>
<td>121</td>
<td>a) Property, Plant and Equipment</td>
<td>683</td>
<td>789</td>
<td>675</td>
</tr>
<tr>
<td>b) Other Equity</td>
<td>3,193</td>
<td>3,353</td>
<td>3,443</td>
<td>b) Capital Work In Progress</td>
<td>120</td>
<td>524</td>
<td>1,483</td>
</tr>
<tr>
<td>c) Non-Controlling Interest</td>
<td>-</td>
<td></td>
<td></td>
<td>c) Investment Property</td>
<td>21</td>
<td>21</td>
<td>138</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>e) Other Intangible Assets</td>
<td>12</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>f) Intangible Assets under Development</td>
<td>78</td>
<td>161</td>
<td>200</td>
</tr>
<tr>
<td><strong>LIABILITIES</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>Financial Liabilities</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>182</td>
<td>1,149</td>
<td>1,202</td>
<td>h) Financial Assets</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(i) Investments</td>
<td>400</td>
<td>657</td>
<td>751</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(ii) Loans</td>
<td>190</td>
<td>288</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(iii) Other Financial Assets</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c) Deferred Tax Liabilities (Net)</td>
<td>11</td>
<td></td>
<td></td>
<td>i) Deferred tax assets (Net)</td>
<td>17</td>
<td>12</td>
<td>-</td>
</tr>
<tr>
<td>d) Other Non-Current Liabilities</td>
<td>17</td>
<td>14</td>
<td>12</td>
<td>j) Income Tax Assets</td>
<td>28</td>
<td>36</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>k) Other Non-Current assets</td>
<td>48</td>
<td>240</td>
<td>130</td>
</tr>
<tr>
<td><strong>Current Liabilities</strong></td>
<td>3,282</td>
<td>3,187</td>
<td>4,064</td>
<td><strong>Current Assets</strong></td>
<td>5,181</td>
<td>5,075</td>
<td>5,374</td>
</tr>
<tr>
<td>a) Financial Liabilities</td>
<td></td>
<td></td>
<td></td>
<td>a) Inventories</td>
<td>1,148</td>
<td>1,093</td>
<td>1,366</td>
</tr>
<tr>
<td>(i) Borrowings</td>
<td>2,003</td>
<td>1,990</td>
<td>2,163</td>
<td>b) Financial Assets</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(ii) Trade Payables</td>
<td>1,142</td>
<td>1,059</td>
<td>1,543</td>
<td>(i) Investments</td>
<td>1,081</td>
<td>33</td>
<td>-</td>
</tr>
<tr>
<td>(iii) Other Financial Liabilities</td>
<td>97</td>
<td>115</td>
<td>262</td>
<td>(ii) Trade Receivables</td>
<td>2,114</td>
<td>2,619</td>
<td>3,065</td>
</tr>
<tr>
<td>b) Other Current Liabilities</td>
<td>33</td>
<td>15</td>
<td>69</td>
<td>(iii) Cash and Cash Equivalents</td>
<td>18</td>
<td>189</td>
<td>11</td>
</tr>
<tr>
<td>c) Provisions</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>(iv) Other Bank balances</td>
<td>96</td>
<td>502</td>
<td>137</td>
</tr>
<tr>
<td>d) Current Tax Liabilities (Net)</td>
<td>3</td>
<td>5</td>
<td>24</td>
<td>(v) Loans</td>
<td>234</td>
<td>161</td>
<td>291</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(vi) Other financial assets</td>
<td>192</td>
<td>221</td>
<td>276</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>c) Other Current Assets</td>
<td>298</td>
<td>257</td>
<td>228</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>d) Asset held for Sale</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GRAND TOTAL - EQUITIES &amp; LIABILITIES</strong></td>
<td>6,778</td>
<td>7,810</td>
<td>8,830</td>
<td><strong>GRAND TOTAL – ASSETS</strong></td>
<td>6,778</td>
<td>7,810</td>
<td>8,830</td>
</tr>
</tbody>
</table>
## Consolidated Income Statement

<table>
<thead>
<tr>
<th>PARTICULARS (INR Mn)</th>
<th>FY17</th>
<th>FY18</th>
<th>FY19</th>
<th>H1-FY20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operational Income</td>
<td>5,469</td>
<td>7,228</td>
<td>8,922</td>
<td>4,824</td>
</tr>
<tr>
<td>Total Expenses</td>
<td>5,187</td>
<td>7,073</td>
<td>8,235</td>
<td>4,168</td>
</tr>
<tr>
<td>EBITDA</td>
<td>282</td>
<td>155</td>
<td>687</td>
<td>656</td>
</tr>
<tr>
<td>EBITDA Margin</td>
<td>5.16%</td>
<td>2.14%</td>
<td>7.70%</td>
<td>13.60%</td>
</tr>
<tr>
<td>Depreciation</td>
<td>218</td>
<td>267</td>
<td>290</td>
<td>153</td>
</tr>
<tr>
<td>Finance Cost</td>
<td>269</td>
<td>284</td>
<td>367</td>
<td>204</td>
</tr>
<tr>
<td>Other Income</td>
<td>145</td>
<td>86</td>
<td>138</td>
<td>13</td>
</tr>
<tr>
<td>Exceptional Items</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Income from Associate</td>
<td>-</td>
<td>2</td>
<td>(1)</td>
<td>-</td>
</tr>
<tr>
<td>PBT</td>
<td>(60)</td>
<td>(308)</td>
<td>167</td>
<td>312</td>
</tr>
<tr>
<td>Tax</td>
<td>16</td>
<td>(68)</td>
<td>137</td>
<td>72</td>
</tr>
<tr>
<td>Profit After Tax</td>
<td>(44)</td>
<td>(240)</td>
<td>30</td>
<td>240</td>
</tr>
<tr>
<td>PAT Margin</td>
<td>NA</td>
<td>-</td>
<td>0.34%</td>
<td>4.98%</td>
</tr>
<tr>
<td>Other Comprehensive Income</td>
<td>(55)</td>
<td>124</td>
<td>5</td>
<td>(56)</td>
</tr>
<tr>
<td>Total Comprehensive Income</td>
<td>(99)</td>
<td>(116)</td>
<td>35</td>
<td>184</td>
</tr>
<tr>
<td>Diluted EPS (INR per share)</td>
<td>(1.25)</td>
<td>(3.01)</td>
<td>0.05</td>
<td>1.85</td>
</tr>
</tbody>
</table>
## Consolidated Balance Sheet (IND-As)

<table>
<thead>
<tr>
<th>PARTICULARS (INR Mn)</th>
<th>FY18</th>
<th>FY19</th>
<th>H1-FY20</th>
<th>PARTICULARS (INR Mn)</th>
<th>FY18</th>
<th>FY19</th>
<th>H1-FY20</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EQUITY</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>Non-Current Assets</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a) Equity Share Capital</td>
<td>4,334</td>
<td>4,303</td>
<td>4,527</td>
<td>a) Property, Plant and Equipment</td>
<td>3,510</td>
<td>4,143</td>
<td>5,179</td>
</tr>
<tr>
<td>b) Other Equity</td>
<td>121</td>
<td>121</td>
<td>121</td>
<td>b) Capital Work In Progress</td>
<td>129</td>
<td>573</td>
<td>1,527</td>
</tr>
<tr>
<td>c) Non-Controlling Interest</td>
<td>3,591</td>
<td>3,588</td>
<td>3,699</td>
<td>c) Investment Property</td>
<td>21</td>
<td>21</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>622</td>
<td>594</td>
<td>707</td>
<td>d) Goodwill</td>
<td>446</td>
<td>444</td>
<td>444</td>
</tr>
<tr>
<td><strong>LIABILITIES</strong></td>
<td></td>
<td></td>
<td></td>
<td>e) Other Intangible Assets</td>
<td>248</td>
<td>205</td>
<td>214</td>
</tr>
<tr>
<td><strong>Non-Current Liabilities</strong></td>
<td></td>
<td></td>
<td></td>
<td>f) Intangible Assets under Development</td>
<td>8</td>
<td>17</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>1,122</td>
<td>1,961</td>
<td>2,032</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Financial Liabilities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a) Borrowings</td>
<td>1,102</td>
<td>1,936</td>
<td>1,993</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b) Provisions</td>
<td>20</td>
<td>24</td>
<td>26</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c) Deferred Tax Liabilities (Net)</td>
<td>1</td>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>d) Other Non-Current Liabilities</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Current Liabilities</strong></td>
<td>4,709</td>
<td>4,604</td>
<td>4,740</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a) Financial Liabilities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(i) Borrowings</td>
<td>2,468</td>
<td>2,443</td>
<td>2,642</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(ii) Trade Payables</td>
<td>1,777</td>
<td>1,646</td>
<td>1,231</td>
<td>(i) Investments</td>
<td>1,081</td>
<td>33</td>
<td>-</td>
</tr>
<tr>
<td>(iii) Other Financial Liabilities</td>
<td>306</td>
<td>366</td>
<td>628</td>
<td>(ii) Trade Receivables</td>
<td>2,053</td>
<td>2,093</td>
<td>1,861</td>
</tr>
<tr>
<td>b) Other Current Liabilities</td>
<td>85</td>
<td>73</td>
<td>144</td>
<td>(iii) Cash and Cash Equivalents</td>
<td>385</td>
<td>532</td>
<td>446</td>
</tr>
<tr>
<td>c) Provisions</td>
<td>70</td>
<td>71</td>
<td>69</td>
<td>(iv) Other Bank balances</td>
<td>96</td>
<td>502</td>
<td>137</td>
</tr>
<tr>
<td>d) Current Tax Liabilities (Net)</td>
<td>3</td>
<td>5</td>
<td>26</td>
<td>(v) Loans</td>
<td>34</td>
<td>31</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(vi) Other financial assets</td>
<td>62</td>
<td>108</td>
<td>161</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>c) Other Current Assets</td>
<td>554</td>
<td>572</td>
<td>495</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>d) Asset held for Sale</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GRAND TOTAL - EQUITIES &amp; LIABILITIES</strong></td>
<td>10,165</td>
<td>10,868</td>
<td>11,299</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GRAND TOTAL – ASSETS</strong></td>
<td>10,165</td>
<td>10,868</td>
<td>11,299</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Consolidated Financial Highlights

**Operational Revenue (INR Mn)**

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>FY16*</th>
<th>FY17</th>
<th>FY18</th>
<th>FY19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>5,042</td>
<td>5,469</td>
<td>7,228</td>
<td>8,922</td>
</tr>
</tbody>
</table>

**EBITDA (INR Mn) & EBITDA Margin (%)**

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>FY16*</th>
<th>FY17</th>
<th>FY18</th>
<th>FY19</th>
</tr>
</thead>
<tbody>
<tr>
<td>EBITDA</td>
<td>917</td>
<td>282</td>
<td>155</td>
<td>687</td>
</tr>
<tr>
<td>Margin</td>
<td>18.19%</td>
<td>5.16%</td>
<td>2.14%</td>
<td>7.70%</td>
</tr>
</tbody>
</table>

**PAT (INR Mn) & PAT Margin (%)**

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>FY16*</th>
<th>FY17</th>
<th>FY18</th>
<th>FY19</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAT</td>
<td>358</td>
<td>-240</td>
<td>-20</td>
<td>30</td>
</tr>
<tr>
<td>Margin</td>
<td>7.10%</td>
<td>-0.80%</td>
<td>-3.32%</td>
<td>0.34%</td>
</tr>
</tbody>
</table>

**Net Debt to Equity**

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>FY16*</th>
<th>FY17</th>
<th>FY18</th>
<th>FY19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Debt to Equity</td>
<td>0.98</td>
<td>1.40</td>
<td>0.83</td>
<td>0.89</td>
</tr>
</tbody>
</table>

*As per I-GAAP
Capital Markets

Share Price Data as on 30th September, 2019

<table>
<thead>
<tr>
<th>Price Data (30th September, 2019)</th>
<th>INR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Face Value</td>
<td>1.00</td>
</tr>
<tr>
<td>Market Price</td>
<td>54.6</td>
</tr>
<tr>
<td>52 Week H/L</td>
<td>66.3/36.7</td>
</tr>
<tr>
<td>Market Cap (Mn)</td>
<td>6,620.5</td>
</tr>
<tr>
<td>Equity Shares Outstanding (Mn)</td>
<td>121.3</td>
</tr>
<tr>
<td>1 Year Avg Trading Volume (’000)</td>
<td>319.7</td>
</tr>
</tbody>
</table>

Shareholding Pattern as on 30th September, 2019

- Public: 55.29%
- Promoters: 22.59%
- DII: 21.19%
- FIIs/Banks: 0.93%
Disclaimer

Camlin Fine Sciences Limited

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be “forward looking statements” based on the currently held beliefs and assumptions of the management of Camlin Fine Science Limited, which are expressed in good faith and in their opinion reasonable, including those relating to the Company’s general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company’s business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

For further details please contact our Investor Relations Representatives:

VALOREM ADVISORS
Mr. Anuj Sonpal
Tel: +91-22-49039500
Email: camlin@valoremadvisors.com
Thank You